课题基金 / 基金详情

Evaluation of end-of-life best practices and implementation of a tool to predict near-term death among patients with metastatic breast cancer in an oncology clinic

Evaluation of end-of-life best practices and implementation of a tool to predict near-term death among patients with metastatic breast cancer in an oncology clinic
评估肿瘤诊所转移性乳腺癌患者的临终最佳实践和实施预测近期死亡的工具
批准号:
10740340
负责人:
Emily Miller Ray
金额:
$16.25万
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
未结题
起止时间:
2023-09-01 至 2028-08-31

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY A “good death” is often desired but seldom delivered for patients with cancer. Because oncologists often do not recognize when a patient is near the end of life (EOL), many patients receive aggressive care until death. To remedy this, prognostic tools are needed to identify patients nearing death. How to incorporate these tools into routine cancer care and use them to prompt best practices, such as serious illness conversations and hospice referrals, is not well understood. The long-term goal is to leverage evidence-based tools to improve EOL care for patients with metastatic breast cancer (MBC). The main objective is to integrate a validated breast cancer prognostic tool into routine practice using implementation science. This research study will pursue three aims: 1) Define the baseline frequency of documented serious illness conversations and hospice referrals among patients with metastatic breast cancer and their relationship to prognostic risk scores; 2) Co-design an implementation protocol with patient, caregiver, and care team partners for use of a metastatic breast cancer prognostic tool in an oncology clinic; and 3) Pilot implementation of a metastatic breast cancer prognostic tool in an oncology clinic and assess implementation outcomes. For the first aim, a retrospective study using EHR data from patients with MBC will quantify baseline EOL best practices and define their relationship to prognostic scores. For the second aim, interviews and user-centered research with oncologists, patients, and caregivers will evaluate factors that impede or enable implementation of the tool in practice and identify desired features of the prognostic tool implementation. These key partners will co-design an implementation protocol. For the third aim, the tool will be piloted in an oncology clinic according to the protocol and evaluated for implementation outcomes using surveys, interviews, and secondary data in a mixed method design. This project seeks to innovate by shifting the paradigm from sole reliance on clinician judgement towards use of evidence-based tools to estimate prognosis. The proposed study is significant for its potential to improve EOL quality for patients with MBC through timely identification of high-risk patients and earlier initiation of EOL best practices. This proposal is submitted by Emily Ray, MD, MPH, a breast medical oncologist and health services researcher at the University of North Carolina in the Cancer Outcomes Research Program. The proposed career development plan will equip her with skills in implementation science, mixed methods, cancer care quality, and multi-site trials to accelerate her research from its evidence basis in large datasets towards interventions aimed at improving cancer care quality. The academic environment at the University of North Carolina, with leading programs in breast oncology, cancer outcomes research, and public health, and her outstanding mentoring team including Dr. Jennifer Leeman, a well-funded, national expert in implementation science, positions Dr. Ray to make an impact through designing, testing, and implementing evidence-based interventions to deliver high-quality, patient-centered end-of-life cancer care.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
真菌特异的内吞作用相关蛋白End3发挥作用的结构研究
  • 批准号:
    32000859
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    24.0万元
  • 批准年份:
    2020
  • 负责人:
    王冬立
  • 依托单位:
峨眉山玄武岩喷发持续时间的研究:来自古地磁学的约束
  • 批准号:
    41804068
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    26.0万元
  • 批准年份:
    2018
  • 负责人:
    徐颖超
  • 依托单位:
从PBMC-β-END-μ-阿片受体途径探讨华蟾素治疗癌痛的外周机制
  • 批准号:
    81173612
  • 项目类别:
    面上项目
  • 资助金额:
    58.0万元
  • 批准年份:
    2011
  • 负责人:
    陈涛
  • 依托单位:
晚期糖基化终产物受体与视网膜母细胞瘤蛋白在前列腺癌细胞中的相互作用及意义
  • 批准号:
    30700835
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    16.0万元
  • 批准年份:
    2007
  • 负责人:
    赵善超
  • 依托单位: